New treatment approaches for relapsing/refractory Hodgkin’s lymphoma: An overview of the Brazilian scenario

Authors

  • Guilherme Perini Hospital Albert Einstein, São Paulo, SP, Brazil.
  • Valeria Buccheri Instituto do Câncer do Estado de São Paulo (Icesp), São Paulo, SP, Brazil.
  • Talita Silveira Faculdade de Ciências Médicas da Santa Casa de São Paulo, São Paulo, SP, Brazil.
  • Adriana Penna Hospital Santa Marcelina, São Paulo, SP, Brazil.
  • Juliano Julio Cerci Quanta, Curitiba, PR, Brazil.
  • Carlos Eduardo Bacchi Laboratório Bacchi, Botucatu, SP, Brazil.
  • Luciana Fanti Evidências – Kantar Health, São Paulo, SP, Brazil.
  • Tânia Barreto Takeda Pharma Brazil, São Paulo, SP, Brazil.

DOI:

https://doi.org/10.21115/JBES.v10.n2.p190-197

Keywords:

Hodgkin’s lymphoma, unmet medical needs, treatments

Abstract

Hodgkin’s lymphoma (HL) is a B-cell malignancy with a classical bimodal distribution with incidence peaking in the third and sixth decades of life. The purpose of this review is to describe the current unmet medical need for relapsing/refractory HL and the main data of emerging treatments, including brentuximab vedotin, the immune checkpoint inhibitors nivolumab and pembrolizumab, as well as other compounds in development. Available guidelines for relapsing/refractory HL are discussed.

Downloads

Download data is not yet available.

Downloads

Published

2018-08-20

How to Cite

Perini, G., Buccheri, V., Silveira, T., Penna, A., Cerci, J. J., Bacchi, C. E., … Barreto, T. (2018). New treatment approaches for relapsing/refractory Hodgkin’s lymphoma: An overview of the Brazilian scenario. Jornal Brasileiro De Economia Da Saúde, 10(2), 190–197. https://doi.org/10.21115/JBES.v10.n2.p190-197

Issue

Vol. 10 No. 2 (2018)

Section

Artigos